Oral insulin can be a blockbuster opportunity: Kiran Mazumdar-Shaw
PUBLISHED ON: November 16, 2012 | Duration: 4 min, 31 sec
Biocon has just brought in Bristol Meyers as a partner for its oral insulin drug. Bristol will fund the clinical trials and, if successful, the rest of the deal will be triggered. Kiran Mazumdar-Shaw, CMD, Biocon, is hopeful of the same and thinks this is a blockbuster opportunity.